Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

(2017) Adrian Vallejo et al.   Nature Communications

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

(2017) Apinya Jusakul et al.   Cancer Discovery

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database

(2016) Kaelan J. Yao et al.   BMC GASTROENTEROLOGY

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism

(2016) Ibrahim E. Elsemman et al.   Molecular BioSystems

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

(2016) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

(2016) S. K. Saha et al.   Cancer Discovery

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

METTL13 is downregulated in bladder carcinoma and suppresses cell proliferation, migration and invasion

(2016) Zhe Zhang et al.   Scientific Reports

Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+/NADPH ratio

(2015) M Itsumi et al.   CELL DEATH AND DIFFERENTIATION

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

(2015) A. Moeini et al.   CLINICAL CANCER RESEARCH

Genomic spectra of biliary tract cancer

(2015) Hiromi Nakamura et al.   NATURE GENETICS

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients

(2014) Qiang Gao et al.   GASTROENTEROLOGY

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

(2014) Supriya K. Saha et al.   NATURE

Only three driver gene mutations are required for the development of lung and colorectal cancers

(2014) Cristian Tomasetti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape of intrahepatic cholangiocarcinoma

(2014) Shanshan Zou et al.   Nature Communications

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

(2014) Bhagwan Yadav et al.   Scientific Reports

Using high-density DNA methylation arrays to profile copy number alterations

(2014) Andrew Feber et al.   GENOME BIOLOGY

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

(2013) Daniela Sia et al.   GASTROENTEROLOGY

Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting

(2013) Alphonse E. Sirica et al.   HEPATOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers

(2013) Waraporn Chan-on et al.   NATURE GENETICS

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma

(2012) M. R. O'Dell et al.   CANCER RESEARCH

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma

(2012) William C. Palmer et al.   JOURNAL OF HEPATOLOGY

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Copy number variation has little impact on bead-array-based measures of DNA methylation

(2009) E. Andrés Houseman et al.   BIOINFORMATICS

Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas

(2009) James E. Everhart et al.   GASTROENTEROLOGY

High lifetime risk of cancer in primary sclerosing cholangitis

(2008) Marian M.H. Claessen et al.   JOURNAL OF HEPATOLOGY